| 6.04 Data as of May 17 |  -0.01 / -0.17%Today’s Change | 3.10 Today|||52-Week Range 7.73 | +15.05% Year-to-Date |
| ARNA Sheds Light on Belviq Launch - Analyst Blog May 09 / Zacks.com | VIVUS Reports Wider Loss - Analyst Blog May 09 / Zacks.com |
| Previous close | 6.05 |
| Today’s open | 6.10 |
| Day’s range | 6.01 - 6.12 |
| Volume | 688,839 |
| Average volume (3 months) | 1,123,787 |
| Market cap | $572.6M |
| Dividend yield | -- |
| Earnings growth (last year) | -118.97% |
| Earnings growth (this year) | +38.21% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | -22.07% |
| P/E ratio | NM |
| Price/Sales | 108.34 |
| Price/Book | 6.77 |
| Today’s change | Today’s % change | |
|---|---|---|
| CCXIChemoCentryx Inc | -0.16 | -1.16% |
| LGNDLigand Pharmaceutica... | +1.32 | +4.95% |
| ICPTIntercept Pharmaceut... | +1.27 | +3.97% |
| MACKMerrimack Pharmaceut... | +0.04 | +0.73% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.19 |
| Annual revenue (last year) | $3.4M |
| Annual profit (last year) | -$90.1M |
| Net profit margin | -2,628.18% |
Sector Health Technology |
Industry Biotechnology |
Chairman Eckard Weber, MD |
President, Chief Executive Officer & Director Michael A. Narachi, MBA |
Corporate headquarters La Jolla, California |
.
